Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International  Study Group

Fizazi, Karim; Tjulandin, Sergei; Salvioni, Roberto; Germà-Lluch, J. R.; Bouzy, J.; Ragan, David; Bokemeyer, Carsten; Gerl, Arthur; Fléchon, Aude; Bono, Johann S. de; Stenning, Sally; Horwich, A.; Pont, Jörg; Albers, Peter; Giorgi, Ugo De; Bower, Mark; Bulanov, A.; Pizzocaro, Giorgio; Aparicio, Jorge; Nichols, Craig R.; Théodore, Christine; Hartmann, Jörg T.; Schmoll, Hans Joachim; Kaye, Stanley B.; Culine, Stéphane; Droz, Jean Pierre; Mahé, Cédric

doi:10.1200/jco.2001.19.10.2647

Cited by 253 publications

(130 citation statements)

References 40 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…[3][4][5][6][7][8] Metastatic mature teratoma is usually treated by surgery alone, whereas the presence of yolk sac tumor requires additional neoadjuvant therapy. [33][34][35] Proliferative or hyperplastic endodermal glandular epithelium of teratoma or rare somatic adenocarcinoma arising from teratoma can mimic glandular yolk sac tumor. [3][4][5][6][7][8] Myxoid/reticular/microcystic yolk sac tumor may also be mistaken as edematous mesodermal teratomatous element or embryonal carcinoma-associated stroma, in particular when yolk sac tumor and embryonal carcinoma/teratoma are intimately associated.…”

Section: Discussionmentioning

confidence: 99%

ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor

Xiao

Unger

et al. 2016

Modern Pathology

View full text Add to dashboard Cite

Although the function of zinc finger and BTB domain containing 16 (ZBTB16) in spermatogenesis is well documented, expression of ZBTB16 in germ cell tumors has not yet been studied. The aim of this study was to investigate the immunohistochemical expression and diagnostic utility of ZBTB16 in germ cell tumors. A total of 67 adult germ cell tumors were studied (62 testicular germ cell tumors, 2 ovarian yolk sac tumors, 1 mediastinal yolk sac tumor, and 2 retroperitoneal metastatic yolk sac tumors). The 62 testicular primary germ cell tumors are as follows: 34 pure germ cell tumors (20 seminomas, 8 embryonal carcinomas, 2 teratomas, 1 choriocarcinoma, 1 carcinoid, and 2 spermatocytic tumors) and 28 mixed germ cell tumors (composed of 13 embryonal carcinomas, 15 yolk sac tumors, 15 teratomas, 7 seminomas, and 3 choriocarcinomas in various combinations). Thirty-five cases contained germ cell neoplasia in situ. Yolk sac tumor was consistently reactive for ZBTB16. Among the 15 testicular yolk sac tumors in mixed germ cell tumors, all displayed moderate to diffuse ZBTB16 staining. ZBTB16 reactivity was present regardless of the histologic patterns of yolk sac tumor and ZBTB16 was able to pick up small foci of yolk sac tumor intermixed/embedded in other germ cell tumor subtype elements. Diffuse ZBTB16 immunoreactivity was also observed in 2/2 metastatic yolk sac tumors, 1/1 mediastinal yolk sac tumor, 2/2 ovarian yolk sac tumors, 2/2 spermatocytic tumors, 1/1 carcinoid, and the spermatogonial cells. All the other non-yolk sac germ cell tumors were nonreactive, including seminoma (n = 27), embryonal carcinoma (n = 21), teratoma (n = 17), choriocarcinoma (n = 4), and germ cell neoplasia in situ (n = 35). The sensitivity and specificity of ZBTB16 in detecting yolk sac tumor among the germ cell tumors was 100% (20/20) and 96% (66/69), respectively. In conclusion, ZBTB16 is a highly sensitive and specific marker for yolk sac tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor

Xiao

Unger

et al. 2016

Modern Pathology

View full text Add to dashboard Cite

show abstract

“…Fizazi et al hebben de distributie van metastasering onderzocht bij 238 patiënten nadat deze waren behandeld met chemotherapie. Zij hadden metastasen in retroperitoneale lymfeklieren (83 %), longen (27 %), mediastinum (15 %), cervicale lymfeklieren (4 %), lever (2 %), bot (1 %) en hersenen (0,5 %) [2]. Indien er sprake is van metastasering kan een multimodaliteitsbehandeling met multipele BEP-kuren in combina-…”

Section: Samenvattingunclassified

Case report. Beleid bij multipele viscerale restlaesies na chemotherapie bij het non-seminoma testis

Valk

Beek

2017

Tijdschr Urol

View full text Add to dashboard Cite

SamenvattingIn dit artikel wordt een 25-jarige patiënt besproken met stadium IV-H non-seminoma testis, met metastasen naar retroperitoneum, longen en lever. Na vier kuren bleomycin, etoposide en cisplatinum (BEP) toonde de patiënt restlaesies op alle metastatische locaties. Chirurgische excisie van alle laesies groter dan 1 cm is gangbaar, omdat de huidige stageringstechnieken de aard van de histologie van de restlaesies niet accuraat kunnen voorspellen. Vanwege de uitgebreidheid van de laesies was chirurgische excisie van alle laesies bij deze patiënt niet haalbaar. Indien radicale chirurgische excisie niet haalbaar wordt geacht, zouden overeenkomsten tussen histologie van verschillende metastatische locaties de beleidskeuze kunnen ondersteunen. Dit artikel beschrijft de histologische overeenkomsten tussen retroperitoneale en viscerale metastasen aan de hand van de literatuur. Ongeveer 30-40 % van de patiënten met een non-seminoom heeft metastasen bij de initiële presentatie [1]. Fizazi et al. hebben de distributie van metastasering onderzocht bij 238 patiënten nadat deze waren behandeld met chemotherapie. Zij hadden metastasen in retroperitoneale lymfeklieren (83 %), longen (27 %), mediastinum (15 %), cervicale lymfeklieren (4 %), lever (2 %), bot (1 %) en hersenen (0,5 %) [2]. Indien er sprake is van metastasering kan een multimodaliteitsbehandeling met multipele BEP-kuren in combina-

show abstract

“…Steyerber, et al reported that histology at residual retroperitoneal lymph node dissection (RPLND) was a strong predictor of histology at thoracotomy (38). However, several authors have reported pathology from residual RPLND to differ from pathology from residual pulmonary nodules in as high as 30% of cases (39)(40)(41)(42). Therefore, pulmonary metastatectomy should be at least considered even in cases with necrosis or fibrosis on RPLND.…”

Section: Germ Cell Tumoursmentioning

confidence: 99%

Results of Pulmonary Resection

Ceppa

2016

Thoracic Surgery Clinics

View full text Add to dashboard Cite

SynopsisPulmonary metastasis can be present in as frequently as 88% and 80%, respectively, of patients with sarcoma and germ cell tumour with metastatic disease. In both sarcoma and germ cell tumour, pulmonary metastatectomy may be the only means of rendering a patient diseasefree. Sublobar (wedge or segmentectomy), lobectomy, and, rarely, pneumonectomy can be safely performed to achieve complete resection. Bilateral disease can be resected via staged thoracoscopy/thoracotomy, median sternotomy, or clamshell thoracotomy. Finally, multiple resections and re-resections in select patients have resulted in improved survival. The main principle of pulmonary metastatectomy is complete resection. In the appropriately selected patient 5-yr survival rates of as high as 35-52% for sarcoma, and 80% for germ cell tumour can be realized. -Large case series of pulmonary metastatectomy of nonseminomatous germ cell tumour (NSGCT) have reported 5-year survival rates greater than 80%.-There are no randomized trials on pulmonary metastatectomy in patients with metastatic sarcoma or NSGCT. Survival rates are from case series of selected patients without observation control arms for comparison.

show abstract

Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group

Cited by 253 publications

References 40 publications

ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor

ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor

Case report. Beleid bij multipele viscerale restlaesies na chemotherapie bij het non-seminoma testis

Results of Pulmonary Resection

Contact Info

Product

Resources

About